MedTrace Logo

4beta-hydroxycholesterol in Cirrhosis

NCT04199910 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-05-05

No results posted yet for this study

Summary

The aim is to evaluate the levels of oxysterols and especially 4beta-hydroxycholesterol in patients with liver cirrhosis. Three cirrhosis cohorts are recruited: patients treated with spironolactone, patients treated with rifaximin, patients without spironolactone or rifaximin. Also three other control cohorts are recruited: patients with pneumonia, patients with Crohn's disease, patients with ulcerative colitis. The effect of the cirrhosis and its medications spironolactone and rifaximin are compared to control groups.

Conditions

  • Cirrhosis, Liver

Interventions

OTHER

There is no intervention, only research blood samples are collected

Research blood samples collected

Sponsors & Collaborators

  • University of Oulu

    lead OTHER

Principal Investigators

  • Janne Hukkanen, MD · Oulu University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04199910 on ClinicalTrials.gov